QARS1

Glutamine--tRNA ligase · P47897 · QARS1 on Sugi Atlas →

169 patent compounds predicted against QARS1, 143 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1893417	0.54	3/20
SCHEMBL5063172	0.69	2/20
Adenosine Phosphate (SCHEMBL7225652)	0.67	2/20
Adenosine Phosphate (SCHEMBL15670721)	0.67	2/20
Adenosine Phosphate (SCHEMBL15670863)	0.59	2/20
SCHEMBL10886080	0.58	2/20
SCHEMBL4750533	0.57	2/20
SCHEMBL3898255	0.56	2/20
SCHEMBL1893409	0.54	2/20
SCHEMBL10883635	0.51	2/20
SCHEMBL5063184	0.78	1/20
SCHEMBL5063189	0.78	1/20
SCHEMBL5067246	0.75	1/20
Adenosine Phosphate (SCHEMBL15670584)	0.74	1/20
Adenosine Triphosphate (SCHEMBL27831091)	0.71	1/20
Adenosine Triphosphate (SCHEMBL28794921)	0.69	1/20
Adenosine Triphosphate (SCHEMBL4419692)	0.68	1/20
Adenosine Triphosphate (SCHEMBL27722788)	0.68	1/20
Adenosine Phosphate (SCHEMBL1331852)	0.67	1/20
SCHEMBL18423487	0.67	1/20

Clinical trials — most relevant to QARS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men	PHASE3	ACTIVE_NOT_RECRUITING
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations	PHASE2	RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Glutamine Supplementation in People With Immune Dysregulation	EARLY_PHASE1	WITHDRAWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes	nan	COMPLETED
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others	nan	RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis	nan	COMPLETED
Study to Identify the Genetic Variations Associated With Phantom Limb Pain	nan	COMPLETED
Genetic Analysis of Immune Disorders	nan	RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Core Stability Exercises and Hereditary Ataxia	nan	COMPLETED
Advancing Neurogenetic Diagnoses Through Long-Read Sequencing	nan	NOT_YET_RECRUITING
Congenital Hemolytic and Dyserythropoietic Anemias	nan	RECRUITING
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Whole Genome Sequencing in the Neonatal Intensive Care Unit	nan	COMPLETED
Genomic of CONgenital Sideroblastic Anemias	nan	RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Genetic Studies Spermatogenic Failure	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Gene Modifiers of Cystic Fibrosis Lung Disease	nan	ACTIVE_NOT_RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Genetics of Primary Ciliary Dyskinesia	nan	COMPLETED
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions	nan	COMPLETED
Gene Analysis of Parkinson's Disease	nan	COMPLETED
Phenotype/Genotype Correlations in Neuromuscular Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a QARS1 binder may also engage these)

Protein	Name	Similarity
Q8BML9	—	1.000	Q8BML9 →
Q66H61	—	1.000	Q66H61 →
Q3MHH4	—	1.000	Q3MHH4 →
Q8W4F3	—	0.979	Q8W4F3 →
P52780	—	0.979	P52780 →
F4I116	—	0.973	F4I116 →
A3KMV5	—	0.971	A3KMV5 →
Q5RGJ5	—	0.971	Q5RGJ5 →
Q9Y105	—	0.971	Q9Y105 →
Q9YH58	—	0.970	Q9YH58 →
P31254	—	0.969	P31254 →
Q5I598	—	0.969	Q5I598 →
Q6YXZ7	—	0.969	Q6YXZ7 →
Q02053	—	0.969	Q02053 →
Q9ER88	—	0.969	Q9ER88 →
Q5U300	—	0.969	Q5U300 →
Q641Y5	—	0.969	Q641Y5 →
Q5I0L3	—	0.969	Q5I0L3 →
Q60HE5	—	0.968	Q60HE5 →
Q7ZY60	—	0.967	Q7ZY60 →
Q9WU20	—	0.967	Q9WU20 →
PRMT5	Protein arginine N-methyltransferase 5	0.967	landscape →
P42898	—	0.966	P42898 →
PC	Pyruvate carboxylase, mitochondrial	0.966	landscape →
Q8BYL4	—	0.966	Q8BYL4 →
A2X0Q3	—	0.966	A2X0Q3 →
NAT10	RNA cytidine acetyltransferase	0.966	landscape →
Q57RP8	—	0.966	Q57RP8 →
ATG7	Ubiquitin-like modifier-activating enzyme ATG7	0.966	landscape →
C5BGA4	—	0.966	C5BGA4 →